ETF Daily News
More M&A Deals Could Boost Biotech ETFs
December 12, 2012
Amgen’s $415 million acquisition of DeCode suggests big-pharma will transition from blockbuster drugs to specialized medicines that target specific areas of the human body, a possibility that could bode well for the biotech sector and its ETFs, according to an article on ETF Trends.
The pursuit for targeted drugs could also benefit from the Obama administration’s push toward health care reform, as the extra insurance coverage would boost demand for medicines, the article said.
For investors seeking a doorway into biotech investments, consider these sector-covering ETFs as a starting point:
Head over to ETFtrends.com to learn more about ETFs within the biotech sector.
Paul and Ugo discuss the rumors surrounding the SEC's new approach to passive ETFs and whether investors have learned any lessons from the recent moves in gold.See All